IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
IRADIMED (NASDAQ: IRMD) has scheduled its 2024 third quarter financial results conference call for October 31st, 2024. The company will release its financial results before market opening, followed by a management-hosted conference call at 11:00 a.m. Eastern Time. Interested participants can register for the call through a provided link, after which they will receive dial-in details and instructions. The call will be available real-time via the internet on the company's website, and a recording will be accessible afterward.
IRADIMED (NASDAQ: IRMD) ha programmato la sua chiamata finanziaria del terzo trimestre 2024 per il 31 ottobre 2024. L'azienda pubblicherà i risultati finanziari prima dell'apertura del mercato, seguiti da una chiamata con la gestione alle 11:00 ora orientale. I partecipanti interessati possono registrarsi per la chiamata tramite un link fornito, dopo di che riceveranno i dettagli per la composizione e le istruzioni. La chiamata sarà disponibile in tempo reale tramite internet sul sito web dell'azienda e una registrazione sarà accessibile in seguito.
IRADIMED (NASDAQ: IRMD) ha programado su llamada de resultados financieros del tercer trimestre de 2024 para el 31 de octubre de 2024. La empresa publicará sus resultados financieros antes de la apertura del mercado, seguida de una llamada de conferencia dirigida por la administración a las 11:00 a.m. hora del este. Los participantes interesados pueden registrarse para la llamada a través de un enlace proporcionado, tras lo cual recibirán los detalles de acceso y las instrucciones. La llamada estará disponible en tiempo real a través de Internet en el sitio web de la empresa, y se podrá acceder a una grabación posteriormente.
IRADIMED (NASDAQ: IRMD)는 2024년 3분기 재무 결과를 발표하는 컨퍼런스 콜을 2024년 10월 31일로 예정했습니다. 회사는 시장 개장 전 재무 결과를 발표한 후 동부 시간 오전 11시에 경영진이 주최하는 컨퍼런스 콜을 진행할 것입니다. 관심이 있는 참가자는 제공된 링크를 통해 콜에 등록할 수 있으며, 이후 전화 접속 세부정보와 지침을 받을 것입니다. 콜은 회사 웹사이트를 통해 실시간으로 인터넷에서 이용 가능하며, 이후 녹음된 내용도 접근할 수 있습니다.
IRADIMED (NASDAQ: IRMD) a programmé sa conférence téléphonique sur les résultats financiers du troisième trimestre 2024 pour le 31 octobre 2024. La société publiera ses résultats financiers avant l'ouverture des marchés, suivis d'une conférence téléphonique animée par la direction à 11h00, heure de l'Est. Les participants intéressés peuvent s'inscrire à l'appel via un lien fourni, après quoi ils recevront les détails de connexion et les instructions. L'appel sera disponible en temps réel sur Internet sur le site web de l'entreprise, et un enregistrement sera accessible par la suite.
IRADIMED (NASDAQ: IRMD) hat seine Konferenzschaltung für die Finanzresultate des dritten Quartals 2024 für den 31. Oktober 2024 angesetzt. Das Unternehmen wird seine finanziellen Ergebnisse vor Öffnung des Marktes bekannt geben, gefolgt von einer von der Geschäftsleitung geleiteten Konferenzschaltung um 11:00 Uhr Eastern Time. Interessierte Teilnehmer können sich über einen bereitgestellten Link für die Schaltung registrieren, nach dem sie die Dial-in-Daten und Anweisungen erhalten. Die Schaltung wird in Echtzeit über das Internet auf der Unternehmenswebsite verfügbar sein, und eine Aufzeichnung wird anschließend zugänglich sein.
- None.
- None.
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here,
https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRADIMED (IRMD) release its Q3 2024 earnings?
What time is IRADIMED's (IRMD) Q3 2024 earnings call?
How can I listen to IRADIMED's (IRMD) Q3 2024 earnings call?
